Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy

艾普沃思嗜睡量表 嗜睡症 安慰剂 猝倒 临床全球印象 医学 白天过度嗜睡 嗜睡 莫达非尼 不利影响 内科学 随机对照试验 物理疗法 麻醉 多导睡眠图 睡眠障碍 失眠症 精神科 呼吸暂停 替代医学 病理
作者
Clete A. Kushida,Colin M. Shapiro,Thomas Roth,Michael J. Thorpy,Bruce Corser,Akinyemi O Ajayi,Russell Rosenberg,Asim Roy,David Seiden,Jordan Dubow,Yves Dauvilliers
出处
期刊:Sleep [Oxford University Press]
卷期号:45 (6) 被引量:36
标识
DOI:10.1093/sleep/zsab200
摘要

To assess the efficacy and safety of FT218, a novel once-nightly formulation of sodium oxybate (ON-SXB), in patients with narcolepsy in the phase 3 REST-ON trial.Narcolepsy patients aged ≥16 years were randomized 1:1 to uptitration of ON-SXB (4.5, 6, 7.5, and 9 g) or placebo. Three coprimary endpoints were change from baseline in mean sleep latency on the Maintenance of Wakefulness Test, Clinical Global Impression-Improvement rating, and weekly cataplexy attacks at 9, 7.5, and 6 g. Secondary endpoints included change from baseline on the Epworth Sleepiness Scale. Safety included adverse drug reactions and clinical laboratory assessments.In total, 222 patients were randomized; 212 received ≥1 dose of ON-SXB (n = 107) or placebo (n = 105). For the three coprimary endpoints and Epworth Sleepiness Scale, all three doses of ON-SXB demonstrated clinically meaningful, statistically significant improvement versus placebo (all p < 0.001). For ON-SXB 9 g versus placebo, increase in mean sleep latency was 10.8 versus 4.7 min (Least squares mean difference, LSMD [95% CI], 6.13 [3.52 to 8.75]), 72.0% versus 31.6% were rated much/very much improved on Clinical Global Impression-Improvement (OR [95% CI], 5.56 [2.76 to 11.23]), change in mean weekly number of cataplexy attacks was -11.5 versus -4.9 (LSMD [95% CI], -6.65 [-9.32 to -3.98]), and change in Epworth Sleepiness Scale was -6.5 and -2.7 (LSMD [95% CI], -6.52 [-5.47 to -2.26]). Common adverse reactions included nausea, vomiting, headache, dizziness, and enuresis.ON-SXB significantly improved narcolepsy symptoms; its safety profile was consistent with SXB. ON-SXB conferred efficacy with a clearly beneficial single nighttime dose.ClinicalTrials.gov: NCT02720744, https://clinicaltrials.gov/ct2/show/NCT02720744.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kiddchow完成签到,获得积分10
刚刚
刚刚
刚刚
跳跃的骁发布了新的文献求助30
刚刚
猪猪发布了新的文献求助10
1秒前
HSA发布了新的文献求助10
2秒前
errui发布了新的文献求助10
2秒前
2秒前
SMHILU发布了新的文献求助10
3秒前
juno完成签到,获得积分10
4秒前
4秒前
霏166发布了新的文献求助10
5秒前
学术丁真完成签到,获得积分20
5秒前
5秒前
华仔应助澡雪采纳,获得10
5秒前
6秒前
Persist发布了新的文献求助10
6秒前
焦立超发布了新的文献求助10
7秒前
量子星尘发布了新的文献求助10
8秒前
9秒前
在水一方应助JJ采纳,获得10
10秒前
10秒前
11秒前
11秒前
ZSJ完成签到,获得积分10
12秒前
12秒前
ZX801发布了新的文献求助10
13秒前
13秒前
善学以致用应助艾小晗采纳,获得20
15秒前
15秒前
sofardli完成签到,获得积分10
15秒前
慕青应助Steven采纳,获得10
15秒前
萩萩完成签到,获得积分10
17秒前
17秒前
wenhao发布了新的文献求助10
18秒前
18秒前
所所应助夏xia采纳,获得10
18秒前
Trends发布了新的文献求助10
18秒前
515发布了新的文献求助10
18秒前
刘述完成签到,获得积分20
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976126
求助须知:如何正确求助?哪些是违规求助? 3520340
关于积分的说明 11202586
捐赠科研通 3256847
什么是DOI,文献DOI怎么找? 1798509
邀请新用户注册赠送积分活动 877645
科研通“疑难数据库(出版商)”最低求助积分说明 806516